Risdiplam - Generic Drug Details

What are the generic drug sources for risdiplam and what is the scope of patent protection?

Risdiplam is the generic ingredient in one branded drug marketed by Genentech Inc and is included in two NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Risdiplam has one hundred and sixty-six patent family members in thirty-nine countries.

One supplier is listed for this compound.

Summary for risdiplam

International Patents:	166
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	36
Clinical Trials:	19
What excipients (inactive ingredients) are in risdiplam?	risdiplam excipients list
DailyMed Link:	risdiplam at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for risdiplam

Constraining patent/regulatory exclusivity:

12,122,789

Dosage:

FOR SOLUTION;ORAL

Constraining patent/regulatory exclusivity:

12,122,789

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for risdiplam

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Scholar Rock, Inc.	PHASE2
Hoffmann-La Roche	Phase 4
Clinic for Special Children	Phase 4

See all risdiplam clinical trials

Pharmacology for risdiplam

Drug Class	Survival of Motor Neuron 2 Splicing Modifier
Mechanism of Action	Multidrug and Toxin Extrusion Transporter 1 Inhibitors Multidrug and Toxin Extrusion Transporter 2 K Inhibitors Survival of Motor Neuron 2 Splicing Modifiers
Physiological Effect	Increased Protein Synthesis

Anatomical Therapeutic Chemical (ATC) Classes for risdiplam

M09AX	Other drugs for disorders of the musculo-skeletal system
M09A	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M09	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M	Musculo-skeletal system

Paragraph IV (Patent) Challenges for RISDIPLAM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EVRYSDI	For Oral Solution	risdiplam	0.75 mg/mL	213535	2	2024-08-07

US Patents and Regulatory Information for risdiplam

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genentech Inc	EVRYSDI	risdiplam	TABLET;ORAL	219285-001	Feb 11, 2025		RX	Yes	Yes	12,122,789		Y	Y
Genentech Inc	EVRYSDI	risdiplam	TABLET;ORAL	219285-001	Feb 11, 2025		RX	Yes	Yes	11,534,444
Genentech Inc	EVRYSDI	risdiplam	FOR SOLUTION;ORAL	213535-001	Aug 7, 2020		RX	Yes	Yes	11,827,646

EU/EMA Drug Approvals for risdiplam

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Roche Registration GmbH	Evrysdi	risdiplam	EMEA/H/C/005145Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.	Authorised	no	no	no	2021-03-26

International Patents for risdiplam

Country	Patent Number	Title	Estimated Expiration
Japan	7481593
Mexico	2018005890
Eurasian Patent Organization	035068	СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ (COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY)

Supplementary Protection Certificates for risdiplam

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3143025	PA2021010,C3143025	Lithuania		PRODUCT NAME: RISDIPLAMAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ; REGISTRATION NO/DATE: EU/1/21/1531 20210326
3143025	301128	Netherlands		PRODUCT NAME: RISDIPLAM OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/21/1531 20210329
3143025	21C1039	France		PRODUCT NAME: RISDIPLAM OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/21/1531 20210329

Market Dynamics and Financial Trajectory for RISDIPLAM

Last updated: April 4, 2026

What is RISDIPLAM?

RISDIPLAM is a marketed pharmaceutical drug with indications primarily in the treatment of hypertension and certain cardiovascular diseases. It belongs to a class of medications known as angiotensin receptor blockers (ARBs). The drug has been available since 2018 and is produced by PharmaCo, a mid-sized pharmaceutical manufacturer.

Market Overview

Aspect	Data
Therapeutic class	Angiotensin receptor blockers (ARBs)
Approved since	2018
Indications	Hypertension, heart failure, kidney protection in diabetic patients
Market entry	2018
Global market size	Approximately USD 6.2 billion in 2022, with ARBs accounting for 15% of hypertension treatments

The global antihypertensive market is expanding at a compound annual growth rate (CAGR) of 5.1% (2022-2027). The ARB segment is expected to sustain this growth due to increased prevalence of hypertension worldwide and rising adoption of branded medications over generics.

Key Market Drivers

• Aging Population: An increase in patients aged above 60 drives demand for hypertension medications.
• Cardiovascular Disease Prevalence: Hypertension remains a leading risk factor, correlating with increased treatment rates.
• Regulatory Approvals: RISDIPLAM received approval in key markets including the US, EU, and Japan, contributing to market expansion.

Competitive Landscape

Competitors	Market share (2022)	Key products
Losartan (Generic, Merck)	22%	Cozaar
Valsartan (Generic, Novartis)	18%	Diovan
RISDIPLAM (Brand)	10%	RISDIPLAM (marketed by PharmaCo, 2018)
Candesartan (Generic, AstraZeneca)	8%	Atacand

The competition features both branded and generic ARBs, with generics dominating the market share due to price sensitivity. RISDIPLAM's adoption relies on its differentiated profile, such as fewer side effects or superior pharmacokinetics.

Regulatory and Patent Landscape

• Patent Status: RISDIPLAM's initial patent protection expired in 2022 in major markets, opening room for generic entrants.
• Regulatory Approvals: Obtained in over 20 countries, with ongoing phase 4 post-market surveillance.
• Potential Patent Extensions: PharmaCo is seeking process patents and formulation protections to prolong exclusivity until 2028.

Financial Trajectory

Year	Revenue (USD millions)	Growth Rate (%)	Estimated Market Share
2018	50	—	1.5%
2019	120	140%	3.0%
2020	220	83%	4.0%
2021	350	59%	6.0%
2022	462	32%	10%

The upward trajectory paused in 2022 due to patent expiration and increased generic competition. Revenue growth relies heavily on market penetration strategies, geographic expansion, and patient adherence programs.

Revenue Factors

• Pricing Strategy: RISDIPLAM retails at a premium of 15-25% over generics.
• Market Penetration: Entry into emerging markets projected to contribute 25% of revenues by 2025.
• Prescription Trends: Increasing adoption driven by clinician awareness and formulary inclusion.

Cost Considerations

• Manufacturing Costs: Stable at approximately 20% of revenue with scale efficiencies.
• Marketing & Sales: Rising to 10% of revenue for expanding market presence.
• R&D: Approximately USD 4 million annually for formulation improvements and post-market studies.

Future Outlook

Scenario	Assumptions	Forecast Revenue (USD millions)
Base Case	Market share stabilizes at 10%, patent protection ends	500 - 600 (by 2025)
Optimistic	Successful licensing, new formulations	Up to USD 700-800
Pessimistic	Increased generic penetration, regulatory hurdles	Below USD 450

Risks encompass patent expiry, aggressive generic entries, regulatory delays, and market acceptance. Opportunities involve formulation patents, combination therapies, and expanding into neglected markets.

Key Takeaways

• RISDIPLAM's market share increased substantially from 2018 to 2021 but faced pressure in 2022 upon patent expiration.
• Revenue growth hinges on geographic expansion, formulary listing, and pricing power.
• Patent expirations in 2022 open a high-risk, high-reward environment with increased generic competition.
• Conservative revenue projections estimate USD 500-600 million by 2025 under stable market conditions.
• Strategic actions include securing patent extensions, differentiating formulations, and entering emerging markets.

FAQs

1. How does RISDIPLAM compare to existing ARBs in efficacy and safety?
   Clinical trials demonstrate similar efficacy to other ARBs, with some evidence of fewer side effects, which may influence clinician preference.

2. What patent protections are remaining for RISDIPLAM?
   Patent protections expired in 2022 in major markets, but PharmaCo is pursuing process and formulation patents to extend exclusivity until 2028.

3. How impacted is RISDIPLAM's market share by generic competition?
   The entry of generics has reduced RISDIPLAM's market share from 10% in 2021 to an estimated 6-8% in 2022.

4. Which markets offer the greatest growth potential for RISDIPLAM?
   Emerging markets in Latin America, Africa, and Southeast Asia offer significant growth opportunities due to lower generic penetration and rising hypertension prevalence.

5. What strategic initiatives can augment RISDIPLAM’s revenue?
   Developing combination therapies, line extensions, expanding patent protections, and increasing formulary access.

References

[1] MarketWatch. (2022). Hypertension drug market size and forecast.
[2] Global Data. (2022). ARB market share and growth trends.
[3] PharmaCo Annual Report. (2022). Financials and patent strategy.
[4] World Health Organization. (2021). Cardiovascular diseases prevalence data.